FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890901246> ?p ?o ?g. }

• W2890901246 endingPage "326" @default.
• W2890901246 startingPage "308" @default.
• W2890901246 abstract "Breast cancer is a severe threat to the health and lives of women due to its difficult early diagnosis and the unsatisfactory therapeutic efficacy of breast cancer treatments. The development of theranostic strategies to combat breast cancer with high accuracy and effectiveness is therefore urgently needed. In this study, we describe a near-infrared (NIR) light-controllable, targeted and biocompatible drug delivery nanoplatform ([email protected]/SPIO-Her) for photoacoustic (PA)/ultrasound (US) bimodal imaging-guided photothermal (PTT)/chemo synergistic cancer therapy of breast cancer. Carboxyl-modified PEGylated poly (lactic-co-glycolic acid) (PLGA-PEG-COOH) constituted the skeleton of the nanoplatform. Especially, the antibody Herceptin was modified onto the surface of nanoplatform for active HER2-targing to facilitate the tumor accumulation of the nanoplatform. The encapsulated superparamagnetic iron oxide (SPIO) nanoparticles could be employed as an excellent PA imaging agent to guide tumor therapy. When exposed to NIR light, the SPIO also could transform NIR light into thermal energy for photothermal ablation of tumor. The NIR-induced thermal effect subsequently triggered the optical droplet vaporization (ODV) of perfluorohexane (PFH) to generate PFH gas bubbles, which not only achieved the US imaging enhancement, but also contributed to the release of loaded paclitaxel (PTX) from the nanoplatform for significantly improving PTT therapeutic efficacy. Our results demonstrated that the targeted tumor accumulation, accurate real-time bimodal imaging, and the abundant drug release at the tumor site were all closely associated with the PTT therapeutic efficacy. Therefore, the theranostic nanoplatform is a very promising strategy for targeted imaging-guided photothermal/chemo synergistic tumor therapy with high therapeutic efficacy and minimized side effects. Breast cancer is the most frequent cancer in women. Herein, we successfully developed a light-controllable and HER2 targeted theranostic nanoparticels ([email protected]/SPIO-Her) as a specific drug delivery nanoplatform to overcome the low accuracy of tumor detection and the low specificity of traditional chemo-therapeutic protocols. The study demonstrated that [email protected]/SPIO-Her could actively target to breast cancer cells with positive HER2 expression. The biocompatible [email protected]/SPIO-Her nanoparticles as both photoacoustic/ultrasound bimodal imaging agents, photothermal-conversion nanomaterials (photothermal hyperthermia) and controllable drug delivery nanoagents (optical droplet vaporization) have completely eradicated the tumor without severe side effects. The theranostic strategy not only integrates strengthens of traditional imaging or therapeutic modalities, but also paves a new way for the efficient cancer treatment by taking the advantage of quickly-developing nanomedicine." @default.
• W2890901246 created "2018-09-27" @default.
• W2890901246 creator A5003218042 @default.
• W2890901246 creator A5016200597 @default.
• W2890901246 creator A5023495158 @default.
• W2890901246 creator A5051489086 @default.
• W2890901246 creator A5055973250 @default.
• W2890901246 creator A5059106560 @default.
• W2890901246 creator A5063616750 @default.
• W2890901246 creator A5082684197 @default.
• W2890901246 creator A5084887446 @default.
• W2890901246 date "2018-10-01" @default.
• W2890901246 modified "2023-10-14" @default.
• W2890901246 title "A light-controllable specific drug delivery nanoplatform for targeted bimodal imaging-guided photothermal/chemo synergistic cancer therapy" @default.
• W2890901246 cites W1971848312 @default.
• W2890901246 cites W1976178939 @default.
• W2890901246 cites W1991699406 @default.
• W2890901246 cites W1994864879 @default.
• W2890901246 cites W2003392370 @default.
• W2890901246 cites W2010456707 @default.
• W2890901246 cites W2010722299 @default.
• W2890901246 cites W2011486625 @default.
• W2890901246 cites W2018384936 @default.
• W2890901246 cites W2023969453 @default.
• W2890901246 cites W2032760352 @default.
• W2890901246 cites W2042758386 @default.
• W2890901246 cites W2045190338 @default.
• W2890901246 cites W2048228776 @default.
• W2890901246 cites W2053026677 @default.
• W2890901246 cites W2061501935 @default.
• W2890901246 cites W2063470712 @default.
• W2890901246 cites W2064301810 @default.
• W2890901246 cites W2071228610 @default.
• W2890901246 cites W2078764716 @default.
• W2890901246 cites W2093305445 @default.
• W2890901246 cites W2096097264 @default.
• W2890901246 cites W2130166533 @default.
• W2890901246 cites W2131442970 @default.
• W2890901246 cites W2136337147 @default.
• W2890901246 cites W2136502605 @default.
• W2890901246 cites W2140239404 @default.
• W2890901246 cites W2320589001 @default.
• W2890901246 cites W2333846688 @default.
• W2890901246 cites W2411698924 @default.
• W2890901246 cites W2550445267 @default.
• W2890901246 cites W2554294021 @default.
• W2890901246 cites W2581440232 @default.
• W2890901246 cites W2588142005 @default.
• W2890901246 cites W2589430454 @default.
• W2890901246 cites W2745729112 @default.
• W2890901246 cites W2766010926 @default.
• W2890901246 cites W2791935253 @default.
• W2890901246 cites W2807515528 @default.
• W2890901246 cites W4381568581 @default.
• W2890901246 doi "https://doi.org/10.1016/j.actbio.2018.09.024" @default.
• W2890901246 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30240955" @default.
• W2890901246 hasPublicationYear "2018" @default.
• W2890901246 type Work @default.
• W2890901246 sameAs 2890901246 @default.
• W2890901246 citedByCount "60" @default.
• W2890901246 countsByYear W28909012462019 @default.
• W2890901246 countsByYear W28909012462020 @default.
• W2890901246 countsByYear W28909012462021 @default.
• W2890901246 countsByYear W28909012462022 @default.
• W2890901246 countsByYear W28909012462023 @default.
• W2890901246 crossrefType "journal-article" @default.
• W2890901246 hasAuthorship W2890901246A5003218042 @default.
• W2890901246 hasAuthorship W2890901246A5016200597 @default.
• W2890901246 hasAuthorship W2890901246A5023495158 @default.
• W2890901246 hasAuthorship W2890901246A5051489086 @default.
• W2890901246 hasAuthorship W2890901246A5055973250 @default.
• W2890901246 hasAuthorship W2890901246A5059106560 @default.
• W2890901246 hasAuthorship W2890901246A5063616750 @default.
• W2890901246 hasAuthorship W2890901246A5082684197 @default.
• W2890901246 hasAuthorship W2890901246A5084887446 @default.
• W2890901246 hasConcept C121608353 @default.
• W2890901246 hasConcept C126322002 @default.
• W2890901246 hasConcept C126511603 @default.
• W2890901246 hasConcept C136229726 @default.
• W2890901246 hasConcept C155672457 @default.
• W2890901246 hasConcept C171250308 @default.
• W2890901246 hasConcept C182606246 @default.
• W2890901246 hasConcept C192562407 @default.
• W2890901246 hasConcept C2777292972 @default.
• W2890901246 hasConcept C2777742735 @default.
• W2890901246 hasConcept C2779820397 @default.
• W2890901246 hasConcept C2780165375 @default.
• W2890901246 hasConcept C502942594 @default.
• W2890901246 hasConcept C530470458 @default.
• W2890901246 hasConcept C71924100 @default.
• W2890901246 hasConceptScore W2890901246C121608353 @default.
• W2890901246 hasConceptScore W2890901246C126322002 @default.
• W2890901246 hasConceptScore W2890901246C126511603 @default.
• W2890901246 hasConceptScore W2890901246C136229726 @default.
• W2890901246 hasConceptScore W2890901246C155672457 @default.
• W2890901246 hasConceptScore W2890901246C171250308 @default.
• W2890901246 hasConceptScore W2890901246C182606246 @default.
• W2890901246 hasConceptScore W2890901246C192562407 @default.

• next